© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer
Affiliations of authors: Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (JW, JPC); Cancer Research Network, Plantation, FL (ETC); Operations Office, National Surgical Breast and Bowel Project and Department of Surgical Oncology Allegheny General Hospital, Pittsburgh, PA (DLW, NW); Division of Pathology, National Surgical Breast and Bowel Project and Department of Pathology, Allegheny General Hospital (SP)
Correspondence to: Jiping Wang, MD, PhD, Biostatistical Center, National Surgical Breast and Bowel Project, University of Pittsburgh, 201 N. Craig St., Ste. 350, Pittsburgh, PA 15213 (e-mail: wang{at}nsabp.pitt.edu)
Background: The risk of invasive breast cancer associated with benign breast disease (BBD) other than atypical hyperplasia and in situ breast cancer, especially with nonproliferative diagnosis, has not been explored extensively. This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD). Methods: 11 307 women without prior history of atypical hyperplasia or in situ breast cancer at randomization (1992–1997) were identified from the cohort of the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention Trial. Pathologic findings from breast biopsy reports through August 2002 were reviewed, and Cox proportional hazards models were used to determine the relative risks (RRs) of breast cancer with 95% confidence intervals (CIs). The relative risks of breast cancer for LC-BBD were adjusted for treatment and for breast cancer risk as determined by the modified Gail model. Results: Of the 11 307 women, 1376 had LC-BBD, of whom 47 developed breast cancer, and of the 9931 women without LC-BBD, 291 developed breast cancer. The RR of breast cancer for women with LC-BBD relative to women without LC-BBD was 1.60 (95% CI = 1.17 to 2.19). Among women 50 years of age and older, the RR of breast cancer for those with LC-BBD was 1.95 (95% CI = 1.29 to 2.93). After adjustment for treatment and breast cancer risk, the RR of breast cancer for women with LC-BBD was 1.41 (95% CI = 1.03 to 1.94). Conclusions: Women with LC-BBD had a statistically significant increased risk of breast cancer. The elevation of breast cancer risk was especially evident in women 50 years of age and older. Furthermore, this risk was independent of that associated with key epidemiologic breast cancer risk factors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Worsham, U. Raju, M. Lu, A. Kapke, J. Cheng, and S. R. Wolman Multiplicity of Benign Breast Lesions Is a Risk Factor for Progression to Breast Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5474 - 5479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Ashbeck, R. D. Rosenberg, P. M. Stauber, and C. R. Key Benign Breast Biopsy Diagnosis and Subsequent Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ding, C. Erdmann, A. M. Chinnaiyan, S. D. Merajver, and C. G. Kleer Identification of EZH2 as a Molecular Marker for a Precancerous State in Morphologically Normal Breast Tissues. Cancer Res., April 15, 2006; 66(8): 4095 - 4099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Arpino, R. Laucirica, and R. M. Elledge Premalignant and In Situ Breast Disease: Biology and Clinical Implications Ann Intern Med, September 20, 2005; 143(6): 446 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hartmann, T. A. Sellers, M. H. Frost, W. L. Lingle, A. C. Degnim, K. Ghosh, R. A. Vierkant, S. D. Maloney, V. S. Pankratz, D. W. Hillman, et al. Benign Breast Disease and the Risk of Breast Cancer N. Engl. J. Med., July 21, 2005; 353(3): 229 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Santen and R. Mansel Benign Breast Disorders N. Engl. J. Med., July 21, 2005; 353(3): 275 - 285. [Full Text] [PDF]
|
|
|
|
 |
|
 C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fiegl, S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel, and M. Widschwendter Circulating Tumor-Specific DNA: A Marker for Monitoring Efficacy of Adjuvant Therapy in Cancer Patients Cancer Res., February 15, 2005; 65(4): 1141 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sun, X. Miao, J. Wang, W. Tan, Y. Zhou, C. Yu, and D. Lin Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma Carcinogenesis, November 1, 2004; 25(11): 2225 - 2230. [Abstract] [Full Text] [PDF]
|
|